PathAI Stock

PathAI is developing cutting-edge technology that promises to better diagnose—and treat—some of today's most challenging diseases.

Sign up today and learn more about PathAI Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About PathAI Stock

PathAI’s services solve the most challenging pathology problems faced by the research and pharmaceutical industry. The PathAI platform provides end-to-end automation for reliable, scalable, and cost-effective long-term solutions. PathAI is developing technology that assists pathologists in making rapid and accurate diagnoses for every patient, every time. The company was founded in 2016 and based in Boston, Massachusetts.


Funding History

December 2016$4.2M
November 2017$11.0M
April 2019$60.0M
November 2019$15.0M


Co-founder & CEO

Andrew Beck

Co-founder & CTO

Aditya Khosla

Senior Software Engineer

Nicholas Vecellio

Independent Product Management Consultant

Gopal Shenoy


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: